A breakthrough study highlights Xenon gas as a potential game-changer in treating Alzheimer’s disease, demonstrating its ...

Anavex Life Sciences shares were up 7% to $11.25 after the company said it saw positive trial results for its oral blarcamesine for the treatment of early Alzheimer's disease. The clinical-stage ...

Dementia, a progressive disorder that impacts memory and independence, affects millions globally. While many are aware of ...

Blarcamesine potential novel oral treatment to target upstream Alzheimer’s disease pathology through autophagy enhancementImpairment of autophagy ...

First Successful Clinical Trial of VU319 Brings Alzheimer's Treatment One Step Closer Dec. 19, 2024 — Phase I clinical trial of a drug was successfully completed, with promise to treat Alzheimer ...

A recent study by Emory University researchers provides new insights into why the mRNA vaccines developed to fight COVID-19 ...

Discover how dopamine’s unexpected role in breaking down harmful plaques could revolutionize Alzheimer's treatment and ...

Advanced brain-on-a-chip technology developed by EU-funded researchers helps make potential treatments for neurological ...

Researchers at the University of Kentucky (UK) are part of a groundbreaking clinical trial exploring the use of medical ...

"In people with progressive cognitive decline, the diagnosis of Alzheimer's disease requires a demonstration of amyloid and ...

A recent study published in Neurology explored whether high doses of nicotinamide, a derivative of vitamin B3, could reduce a ...

The Alzheimer’s disease market is expected to grow at a CAGR of 23.4% from $2.4bn in 2023 to $19.3bn by 2033 across the 8MM ...